PL1812797T3 - Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom - Google Patents

Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom

Info

Publication number
PL1812797T3
PL1812797T3 PL05818382T PL05818382T PL1812797T3 PL 1812797 T3 PL1812797 T3 PL 1812797T3 PL 05818382 T PL05818382 T PL 05818382T PL 05818382 T PL05818382 T PL 05818382T PL 1812797 T3 PL1812797 T3 PL 1812797T3
Authority
PL
Poland
Prior art keywords
prevention
compositions
treatment
methods
hyperproliferative diseases
Prior art date
Application number
PL05818382T
Other languages
English (en)
Inventor
Roger A Sabbadini
Amy L Cavalli
William Garland
Original Assignee
Lpath Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lpath Inc filed Critical Lpath Inc
Publication of PL1812797T3 publication Critical patent/PL1812797T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05818382T 2004-10-28 2005-10-28 Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom PL1812797T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62319704P 2004-10-28 2004-10-28
EP05818382A EP1812797B1 (en) 2004-10-28 2005-10-28 Compositions and methods for the treatment and prevention of hyperproliferative diseases
PCT/US2005/039303 WO2006078336A2 (en) 2004-10-28 2005-10-28 Compositions and methods for the treatment and prevention of hyperproliferative diseases

Publications (1)

Publication Number Publication Date
PL1812797T3 true PL1812797T3 (pl) 2013-08-30

Family

ID=36692680

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05818382T PL1812797T3 (pl) 2004-10-28 2005-10-28 Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom

Country Status (10)

Country Link
EP (1) EP1812797B1 (pl)
JP (1) JP4982377B2 (pl)
AU (1) AU2005325227B2 (pl)
CA (1) CA2581061C (pl)
DK (1) DK1812797T3 (pl)
ES (1) ES2410866T3 (pl)
PL (1) PL1812797T3 (pl)
PT (1) PT1812797E (pl)
SI (1) SI1812797T1 (pl)
WO (1) WO2006078336A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
KR101581279B1 (ko) * 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
CN101687031B (zh) * 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
WO2008154470A1 (en) * 2007-06-08 2008-12-18 University Of Connecticut Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye
WO2017015334A1 (en) * 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
AU2017376922B2 (en) 2016-12-15 2022-12-01 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260288A (en) * 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
JPH09176083A (ja) * 1995-12-28 1997-07-08 Sankyo Co Ltd 新規化合物ｆ−１２５０９ａ
US6423527B1 (en) * 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
ATE409486T1 (de) * 1998-06-29 2008-10-15 Children S Hospital Los Angele Behandlung hyperproliferativer erkrankungen
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
WO2002017899A2 (en) * 2000-08-31 2002-03-07 University Of Connecticut Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration
US20030096022A1 (en) * 2000-12-22 2003-05-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US7674580B2 (en) * 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
NZ560662A (en) * 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer

Also Published As

Publication number Publication date
WO2006078336A3 (en) 2006-11-30
JP4982377B2 (ja) 2012-07-25
JP2008518946A (ja) 2008-06-05
CA2581061C (en) 2014-09-02
CA2581061A1 (en) 2006-07-27
AU2005325227A1 (en) 2006-07-27
PT1812797E (pt) 2013-05-21
EP1812797A4 (en) 2009-04-29
HK1102626A1 (en) 2007-11-30
AU2005325227B2 (en) 2012-11-01
DK1812797T3 (da) 2013-05-21
ES2410866T3 (es) 2013-07-03
SI1812797T1 (sl) 2013-06-28
WO2006078336A2 (en) 2006-07-27
EP1812797B1 (en) 2013-03-20
EP1812797A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200704677B (en) Compositions and methods for the treatment of autism
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
IL178860A (en) Certain chemical entities, preparations and processes
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
IL174627A0 (en) Compositions and methods for treatment of burns
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
EP1812797A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERPROLIFERATIVE DISEASES
EP1740221A4 (en) METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
GB0426196D0 (en) Methods of treatment
GB2441094B (en) Methods for treatment and prevention of infection
EP1781318A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
IL179039A0 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB0504657D0 (en) Compositions and methods of treatment